

Alessandro Rizzo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4912847/alessandro-rizzo-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

108
papers

1,292
citations

22
h-index

31
g-index

150
ext. papers

2,664
ext. citations

4.7
avg, IF

6.42
L-index

#	Paper	IF	Citations
108	Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives. <i>Cancer Genomics and Proteomics</i> , 2020 , 17, 441-452	3.3	55
107	PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer. <i>Cancers</i> , 2021 , 13,	6.6	54
106	Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 317-324	5.9	45
105	Evolution of the Experimental Models of Cholangiocarcinoma. <i>Cancers</i> , 2020 , 12,	6.6	44
104	Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. <i>Immunotherapy</i> , 2021 , 13, 637-644	3.8	44
103	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	38
102	Recent advances of immunotherapy for biliary tract cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 527-536	4.2	38
101	Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience. <i>International Journal of Hyperthermia</i> , 2020 , 37, 479-485	3.7	34
100	Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow. <i>Anticancer Research</i> , 2020 , 40, 3013-3030	2.3	34
99	Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 1329-1338	4.1	34
98	Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. <i>Cancer Treatment and Research Communications</i> , 2021 , 27, 100328	2	33
97	Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis. <i>In Vivo</i> , 2020 , 34, 479-488	2.3	32
96	Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 156, 103119	7	31
95	Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept. <i>Scientific Reports</i> , 2018 , 8, 9997	4.9	31
94	Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis. <i>Future Oncology</i> , 2020 , 16, 4409-4418	3.6	30
93	The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box?. <i>ESMO Open</i> , 2020 , 5, e001042	6	25
92	Is There a Role for Immunotherapy in Prostate Cancer?. <i>Cells</i> , 2020 , 9,	7.9	25

91	Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. <i>Cancer Treatment and Research Communications</i> , 2021 , 27, 100337	2	25
90	Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 1-8	5.9	24
89	Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 547-554	4.2	22
88	Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021 , 154, 120-127	7.5	22
87	Current status of the adjuvant therapy in uterine sarcoma: A literature review. <i>World Journal of Clinical Cases</i> , 2019 , 7, 1753-1763	1.6	18
86	BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 483-485	4.2	18
85	Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. <i>European Urology Focus</i> , 2021 ,	5.1	17
84	Tumor-Associated Macrophages and Inflammatory Microenvironment in Gastric Cancer: Novel Translational Implications. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	14
83	First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!". <i>Cancer Treatment and Research Communications</i> , 2021 , 27, 100335	2	14
82	PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 1-9	5.9	14
81	Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile. <i>Cancers</i> , 2020 , 12,	6.6	13
80	Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 343-350	5.9	13
79	Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: Another Paradigm Shift?. <i>Cancers</i> , 2021 , 13,	6.6	12
78	Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2021 ,	5.1	12
77	Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. <i>Cancer Treatment and Research Communications</i> , 2021 , 27, 100354	2	11
76	Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920936932	5.4	10
75	Specific Toxicity of Maintenance Olaparib Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis. <i>Anticancer Research</i> , 2020 , 40, 597-608	2.3	9
74	IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?. <i>Cancer Treatment and Research Communications</i> , 2021 , 27, 100356	2	9

73	The (Eternal) Debate on Microwave Ablation Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma. <i>In Vivo</i> , 2020 , 34, 3421-3429	2.3	8
72	Treating Prostate Cancer by Antibody-Drug Conjugates. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	8
71	How to Choose Between Percutaneous Transhepatic and Endoscopic Biliary Drainage in Malignant Obstructive Jaundice: An Updated Systematic Review and Meta-analysis. <i>In Vivo</i> , 2020 , 34, 1701-1714	2.3	7
70	Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 755-763	3.5	7
69	Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis. <i>Cancers</i> , 2020 , 12,	6.6	7
68	First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 1245-1251	4.2	7
67	Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 491-501	3.5	6
66	Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 1-7	5.9	6
65	PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?. <i>Medicines (Basel, Switzerland)</i> , 2020 , 7,	4.1	6
64	Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis. <i>Immunotherapy</i> , 2021 , 13, 257-270	3.8	6
63	Recurrent Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential (STUMP): State of The Art. <i>Anticancer Research</i> , 2020 , 40, 1229-1238	2.3	5
62	Regarding "HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer". <i>Oncologist</i> , 2020 , 25, e1818	5.7	5
61	The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory?. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
60	Experimental HER2- targeted therapies for biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 389-399	5.9	5
59	In Regard to "A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)". <i>Oncologist</i> , 2021 , 26, e902	5.7	5
58	Microbiota and prostate cancer. <i>Seminars in Cancer Biology</i> , 2021 ,	12.7	5
57	Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?. <i>Frontiers in Oncology</i> , 2021 , 11, 803133	5.3	5
56	Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2021 , 17, 61	5	5

55	Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022 , 1-7	4.2	5
54	Avelumab Maintenance for Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2020 , 383, 2482	59.2	4
53	Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures. <i>Cancers</i> , 2020 , 12,	6.6	4
52	Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 1-9	5.9	4
51	Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos. <i>Cancer Genetics</i> , 2020 , 248-249, 57-62	2.3	4
50	Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. <i>Immunotherapy</i> , 2021 , 13, 685-692	3.8	4
49	Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials. <i>Pathology Research and Practice</i> , 2021 , 222, 153440	3.4	4
48	Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 1225-1232	4.2	4
47	Targeted therapy in deficient GIST. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211023278	3.4	4
46	Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis.. <i>Cancers</i> , 2022 , 14,	6.6	4
45	An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT.. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
44	Combination therapy of dabrafenib plus trametinib in patients with BRAF-mutated biliary tract cancer. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021 , 20, 506-507	2.1	3
43	FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 567-574	4.2	3
42	Hacking Pancreatic Cancer: Present and Future of Personalized Medicine. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	3
41	The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST). <i>Cancers</i> , 2021 , 13,	6.6	3
40	Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing. <i>Pathology Research and Practice</i> , 2021 , 219, 153350	3.4	3
39	Re: Toni K. Choueiri, Daniel Y.C. Heng, Jae Lyun Lee, et al. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. <i>JAMA Oncol</i> . In press. https://doi.org/10.1001/jamaoncol.2020.2218 : SAVOIR: From Own Goal to Winning Goal?. <i>European Urology Oncology</i> , 2020 , 3, 561-562	6.7	2
38	Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.. <i>Current Oncology</i> , 2022 , 29, 551-564	2.8	2

37	Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis.. <i>Future Oncology</i> , 2022 ,	3.6	2
36	Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges. <i>Cancer Control</i> , 2020 , 27, 1073274820983013	2.2	2
35	A foreword on biliary tract cancers: emerging treatments, drug targets, and fundamental knowledge gaps. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 279	5.9	2
34	TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?-a narrative review. <i>Translational Andrology and Urology</i> , 2021 , 10, 1541-1552	2.3	2
33	Quality of life assessment in renal cell carcinoma—Phase II and III clinical trials published between 2010 and 2020: a systematic review. <i>Future Oncology</i> , 2021 , 17, 2671-2681	3.6	2
32	Gene Expression Landscape of SDH-Deficient Gastrointestinal Stromal Tumors. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
31	Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges. <i>Current Oncology</i> , 2021 , 28, 3393-3402	2.8	2
30	Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions. <i>Cancer Treatment and Research Communications</i> , 2021 , 27, 100334	2	2
29	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.. <i>European Urology Focus</i> , 2022 ,	5.1	2
28	Granular cell tumor of the trachea as a rare cause of dyspnea in a young woman. <i>Respiratory Medicine Case Reports</i> , 2019 , 28, 100961	1.2	1
27	Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer.. <i>Lancet Oncology, The</i> , 2022 , 23, e11	21.7	1
26	Nivolumab plus ipilimumab in melanoma brain metastases.. <i>Lancet Oncology, The</i> , 2022 , 23, e52	21.7	1
25	Immune-based combinations for metastatic triple negative breast cancer in clinical trials: Current knowledge and therapeutic prospects. <i>Expert Opinion on Investigational Drugs</i> , 2021 ,	5.9	1
24	The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: will immunotherapy solve the problem?. <i>Immunotherapy</i> , 2022 ,	3.8	1
23	Pancreatic mucinous cystadenocarcinoma in a patient harbouring germline mutation effectively treated with olaparib: A case report. <i>World Journal of Gastrointestinal Oncology</i> , 2020 , 12, 1456-1463	3.4	1
22	Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience. <i>Pathology Research and Practice</i> , 2021 , 220, 153410	3.4	1
21	Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors. <i>Medicina (Lithuania)</i> , 2021 , 57,	3.1	1
20	Adjuvant immunotherapy in muscle-invasive urothelial carcinoma. <i>Lancet Oncology, The</i> , 2021 , 22, e237	21.7	1

19	Nivolumab: an investigational agent for the treatment of biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 325-332	5.9	1
18	Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 1237-1243	5.5	1
17	An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 2323-2336	4	1
16	Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report. <i>Medicines (Basel, Switzerland)</i> , 2021 , 8,	4.1	1
15	The Last Dance for Chemotherapy Intensification in Non-Asian Advanced Biliary Tract Cancers?. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102509	2.2	1
14	Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. <i>Cancers</i> , 2022 , 14, 2429	6.6	1
13	Chemoimmunotherapy versus immune checkpoint inhibitors monotherapy as first-line treatment for advanced non-small cell lung cancer.. <i>Thoracic Cancer</i> , 2022 ,	3.2	0
12	Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis. <i>Immunotherapy</i> , 2021 , 13, 783-793	3.8	0
11	Fluoropyrimidine-based doublet chemotherapy as second-line treatment for advanced biliary tract cancer: a meta-analysis of ABC-06 and NIFTY.. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022 , 1-6	4.2	0
10	Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward. <i>Medicina (Lithuania)</i> , 2022 , 58, 600	3.1	0
9	Genomics and Immunomics in the Treatment of Urothelial Carcinoma. <i>Current Oncology</i> , 2022 , 29, 3499-3518	3.8	0
8	Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2022 , 7, 50-57	1.6	0
7	The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2022 , 12, 842	3.6	0
6	Optimizing outcomes in HCC: Comment on "optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis" by Jiang et al. <i>Translational Oncology</i> , 2021 , 14, 101246	4.9	
5	Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021 , 6, 217-224	1.6	
4	Safety profile of immune checkpoint inhibitors versus sorafenib as first-line treatment in advanced hepatocellular carcinoma: A meta-analysis of randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 315-315	2.2	
3	FGFR Inhibitors in Cholangiocarcinoma: A Real-World Experience at a Tertiary Center.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100511	3.6	
2	Radiofrequency ablation, radiation therapy, transarterial chemoembolization, and yttrium 90: no differences for local treatment of liver cancer?. <i>Acta Oncologica</i> , 2022 , 1	3.2	

- 1 Adenosine pathway inhibitors: novel investigational agents for the treatment of metastatic breast cancer.. *Expert Opinion on Investigational Drugs*, **2022**, 1-7 5.9